
### [MONDO:0018118](http://purl.obolibrary.org/obo/MONDO_0018118)
**Label:** disorder of phospholipids, sphingolipids and fatty acids biosynthesis with central nervous system predominant involvement

**Subclasses:** [MONDO:0017998](http://purl.obolibrary.org/obo/MONDO_0017998) (PLA2G6-associated neurodegeneration), [MONDO:0009739](http://purl.obolibrary.org/obo/MONDO_0009739) (neurodegeneration with brain iron accumulation 2a), [MONDO:0018274](http://purl.obolibrary.org/obo/MONDO_0018274) (GM3 synthase deficiency), [MONDO:0012189](http://purl.obolibrary.org/obo/MONDO_0012189) (Amish infantile epilepsy syndrome), [MONDO:0009319](http://purl.obolibrary.org/obo/MONDO_0009319) (pantothenate kinase-associated neurodegeneration), 

**Corr. equiv. classes:** [Orphanet:370933](http://www.orpha.net/ORDO/Orphanet_370933), [OMIM:256600](http://purl.obolibrary.org/obo/OMIM_256600), [Orphanet:171714](http://www.orpha.net/ORDO/Orphanet_171714), [Orphanet:157850](http://www.orpha.net/ORDO/Orphanet_157850), [OMIM:610217](http://purl.obolibrary.org/obo/OMIM_610217), [Orphanet:35069](http://www.orpha.net/ORDO/Orphanet_35069), [OMIM:234200](http://purl.obolibrary.org/obo/OMIM_234200), [OMIM:609056](http://purl.obolibrary.org/obo/OMIM_609056), [Orphanet:329303](http://www.orpha.net/ORDO/Orphanet_329303), 

**Class expressions from DL-Learner:**

- [HP:0002180](http://purl.obolibrary.org/obo/HP_0002180) (Neurodegeneration) and [HP:0007256](http://purl.obolibrary.org/obo/HP_0007256) (Abnormal pyramidal signs) 55.40%
- [HP:0002180](http://purl.obolibrary.org/obo/HP_0002180) (Neurodegeneration) and [HP:0007256](http://purl.obolibrary.org/obo/HP_0007256) (Abnormal pyramidal signs) and [HP:0100022](http://purl.obolibrary.org/obo/HP_0100022) (Abnormality of movement) 55.40%
- [HP:0002180](http://purl.obolibrary.org/obo/HP_0002180) (Neurodegeneration) and [HP:0007256](http://purl.obolibrary.org/obo/HP_0007256) (Abnormal pyramidal signs) and [HP:0012823](http://purl.obolibrary.org/obo/HP_0012823) (Clinical modifier) 55.40%
- [HP:0002180](http://purl.obolibrary.org/obo/HP_0002180) (Neurodegeneration) and [HP:0003011](http://purl.obolibrary.org/obo/HP_0003011) (Abnormality of the musculature) and [HP:0007256](http://purl.obolibrary.org/obo/HP_0007256) (Abnormal pyramidal signs) 55.40%
- [HP:0002180](http://purl.obolibrary.org/obo/HP_0002180) (Neurodegeneration) and [HP:0007256](http://purl.obolibrary.org/obo/HP_0007256) (Abnormal pyramidal signs) and [HP:0012823](http://purl.obolibrary.org/obo/HP_0012823) (Clinical modifier) and [HP:0100022](http://purl.obolibrary.org/obo/HP_0100022) (Abnormality of movement) 55.40%
- [HP:0002180](http://purl.obolibrary.org/obo/HP_0002180) (Neurodegeneration) and [HP:0003011](http://purl.obolibrary.org/obo/HP_0003011) (Abnormality of the musculature) and [HP:0007256](http://purl.obolibrary.org/obo/HP_0007256) (Abnormal pyramidal signs) and [HP:0100022](http://purl.obolibrary.org/obo/HP_0100022) (Abnormality of movement) 55.40%
- [HP:0002180](http://purl.obolibrary.org/obo/HP_0002180) (Neurodegeneration) and [HP:0003011](http://purl.obolibrary.org/obo/HP_0003011) (Abnormality of the musculature) and [HP:0007256](http://purl.obolibrary.org/obo/HP_0007256) (Abnormal pyramidal signs) and [HP:0012823](http://purl.obolibrary.org/obo/HP_0012823) (Clinical modifier) 55.40%
- [HP:0002180](http://purl.obolibrary.org/obo/HP_0002180) (Neurodegeneration) and [HP:0003011](http://purl.obolibrary.org/obo/HP_0003011) (Abnormality of the musculature) and [HP:0012823](http://purl.obolibrary.org/obo/HP_0012823) (Clinical modifier) 52.02%
- [HP:0002180](http://purl.obolibrary.org/obo/HP_0002180) (Neurodegeneration) and [HP:0012823](http://purl.obolibrary.org/obo/HP_0012823) (Clinical modifier) and [HP:0100022](http://purl.obolibrary.org/obo/HP_0100022) (Abnormality of movement) 49.40%
- [HP:0002180](http://purl.obolibrary.org/obo/HP_0002180) (Neurodegeneration) and [HP:0002493](http://purl.obolibrary.org/obo/HP_0002493) (Upper motor neuron dysfunction) and [HP:0012823](http://purl.obolibrary.org/obo/HP_0012823) (Clinical modifier) 49.40%
- [HP:0002180](http://purl.obolibrary.org/obo/HP_0002180) (Neurodegeneration) and [HP:0012823](http://purl.obolibrary.org/obo/HP_0012823) (Clinical modifier) 47.29%
- [HP:0002180](http://purl.obolibrary.org/obo/HP_0002180) (Neurodegeneration) and [HP:0100022](http://purl.obolibrary.org/obo/HP_0100022) (Abnormality of movement) 45.53%
- [HP:0002180](http://purl.obolibrary.org/obo/HP_0002180) (Neurodegeneration) and [HP:0003011](http://purl.obolibrary.org/obo/HP_0003011) (Abnormality of the musculature) 45.53%
- [HP:0002180](http://purl.obolibrary.org/obo/HP_0002180) (Neurodegeneration) and [HP:0002493](http://purl.obolibrary.org/obo/HP_0002493) (Upper motor neuron dysfunction) 45.53%
- [HP:0002180](http://purl.obolibrary.org/obo/HP_0002180) (Neurodegeneration) and [HP:0011442](http://purl.obolibrary.org/obo/HP_0011442) (Abnormality of central motor function) 42.78%


